Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. https://doi.org/10.1002/IJC.33588.
   Web of Science ®Google Scholar
• Rehman U, Parveen N, Sheikh A, et al. Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer. Colloids Surf B Biointerfaces. 2022;218:112766. https://doi.org/10.1016/J.COLSURFB.2022.112766.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mukherjee S, Abourehab MAS, et al. Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy. Eur Polym J. 2022;177:111471. https://doi.org/10.1016/J.EURPOLYMJ.2022.111471.
   Web of Science ®Google Scholar
• Singh V, Sheikh A, Abourehab MAS, et al. Dostarlimab as a miracle drug: rising hope against cancer treatment. Biosensors (Basel). 2022;12(8):617. https://doi.org/10.3390/BIOS12080617.
   PubMedGoogle Scholar
• Jain AK, Jain S, Abourehab MAS, et al. An insight on topically applied formulations for management of various skin disorders. J Biomater Sci Polym Ed. 2022;1–27. https://doi.org/10.1080/09205063.2022.2103625.
   Google Scholar
• Gupta P, Sheikh A, Abourehab MAS, et al. Amelioration of full-thickness wound using hesperidin loaded dendrimer-based hydrogel bandages. Biosens. 2022;12(7):462. https://doi.org/10.3390/BIOS12070462.
   PubMedGoogle Scholar
• Hussain Z, Rahim MA, Jan N, et al. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy. J Control Release. 2021;335:130–157. https://doi.org/10.1016/J.JCONREL.2021.05.018.
   PubMed Web of Science ®Google Scholar
• Qiao J, Liu Z, Fu YX. Adapting conventional cancer treatment for immunotherapy. J Mol Med (Berl). 2016;94(5):489–495. https://doi.org/10.1007/S00109-016-1393-4.
   PubMed Web of Science ®Google Scholar
• Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Support Palliat Care. 2007;1(1):57–62. https://doi.org/10.1097/SPC.0B013E32813A328F.
   PubMedGoogle Scholar
• Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245. https://doi.org/10.3389/FPHAR.2018.00245.
   PubMed Web of Science ®Google Scholar
• Nounou MI, Elamrawy F, Ahmed N, et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl). 2015;9(Suppl 2):17–34. https://doi.org/10.4137/BCBCR.S29420.
   PubMedGoogle Scholar
• Mirza Z, Karim S. Advancements in CRISPR/Cas9 technology-focusing on cancer therapeutics and beyond. Semin Cell Dev Biol. 2019;96:13–21. https://doi.org/10.1016/J.SEMCDB.2019.05.026.
   PubMed Web of Science ®Google Scholar
• Barrangou R, Marraffini LA. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Mol Cell. 2014;54(2):234–244. https://doi.org/10.1016/J.MOLCEL.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262–1278. https://doi.org/10.1016/J.CELL.2014.05.010.
   PubMed Web of Science ®Google Scholar
• Long C, Amoasii L, Bassel-Duby R, et al. Genome editing of monogenic neuromuscular diseases: a systematic review. JAMA Neurol. 2016;73(11):1349–1355. https://doi.org/10.1001/JAMANEUROL.2016.3388.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu C, Wang Y, et al. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev. 2021;176:113891. https://doi.org/10.1016/J.ADDR.2021.113891.
   PubMed Web of Science ®Google Scholar
• Tycko J, Myer VE, Hsu PD. Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol Cell. 2016;63(3):355–370. https://doi.org/10.1016/J.MOLCEL.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Klann TS, Black JB, Chellappan M, et al. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol. 2017;35(6):561–568. https://doi.org/10.1038/NBT.3853.
   PubMed Web of Science ®Google Scholar
• Deschler B, Lübbert M. Acute myeloid leukemia: Epidemiology and etiology. Acute Leuk. 2008;47–56. https://doi.org/10.1007/978-3-540-72304-2_3.
   Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. https://doi.org/10.1016/J.BLRE.2019.04.005.
   PubMed Web of Science ®Google Scholar
• Yan J, Kang DD, Turnbull G, et al. Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer. Adv Drug Deliv Rev. 2022;180:114042. https://doi.org/10.1016/J.ADDR.2021.114042.
   PubMed Web of Science ®Google Scholar
• Pandol S, Edderkaoui M, Gukovsky I, et al. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S44–S47. https://doi.org/10.1016/J.CGH.2009.07.039.
   PubMed Web of Science ®Google Scholar
• Ying H, Dey P, Yao W, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30(4):355–385. https://doi.org/10.1101/GAD.275776.115.
   PubMed Web of Science ®Google Scholar
• Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218–1249. https://doi.org/10.1101/GAD.1415606.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Shimada S, Akiyama Y, et al. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Int J Cancer. 2019;145(1):192–205. https://doi.org/10.1002/IJC.32072.
   PubMed Web of Science ®Google Scholar
• Pessolano E, Belvedere R, Bizzarro V, et al. Annexin A1 may induce pancreatic cancer progression as a key player of extracellular vesicles effects as evidenced in the in vitro MIA PaCa-2 model system. Int J Mol Sci. 2018;19(12):3878. https://doi.org/10.3390/IJMS19123878.
   PubMed Web of Science ®Google Scholar
• Stintzing S. Management of colorectal cancer. F1000Prime Rep. 2014;6:108. https://doi.org/10.12703/P6-108.
   PubMedGoogle Scholar
• Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–465. https://doi.org/10.1016/J.CURRPROBLCANCER.2018.06.003.
   PubMed Web of Science ®Google Scholar
• Hull R, Mbele M, Makhafola T, et al. Cervical cancer in low and middle-income countries (Review). Oncol Lett. 2020;20(3):2058–2074. https://doi.org/10.3892/OL.2020.11754/HTML.
   PubMed Web of Science ®Google Scholar
• Jubair L, Lam AK, Fallaha S, et al. CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice. PLoS One. 2021;16(1):e0223288. https://doi.org/10.1371/JOURNAL.PONE.0223288.
   PubMed Web of Science ®Google Scholar
• Ling K, Yang L, Yang N, et al. Gene targeting of HPV18 E6 and E7 synchronously by nonviral transfection of CRISPR/Cas9 system in cervical cancer. Hum Gene Ther. 2020;31(5–6):297–308. https://doi.org/10.1089/HUM.2019.246/ASSET/IMAGES/LARGE/HUM.2019.246_FIGURE8.JPEG.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Roseblade A, Hansbro PM, et al. Nanoparticles in cancer treatment: opportunities and obstacles. Curr Drug Targets. 2018;19(14):1696–1709. https://doi.org/10.2174/1389450119666180326122831.
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62(2):90–99. https://doi.org/10.1016/J.PHRS.2010.03.005.
   PubMed Web of Science ®Google Scholar
• Song R, Murphy M, Li C, et al. Current development of biodegradable polymeric materials for biomedical applications. Drug Des Devel Ther. 2018;12:3117–3145. https://doi.org/10.2147/DDDT.S165440.
   PubMed Web of Science ®Google Scholar
• Shaikh A, Kesharwani P, Gajbhiye V. Dendrimer as a momentous tool in tissue engineering and regenerative medicine. J Control Release. 2022;346:328–354. https://doi.org/10.1016/J.JCONREL.2022.04.008.
   PubMed Web of Science ®Google Scholar
• Kumar Dubey S, Dabholkar N, Narayan Pal U, et al. Emerging innovations in cold plasma therapy against cancer: a paradigm shift. Drug Discov. Today. 2022;27(9):2425–2439. https://doi.org/10.1016/J.DRUDIS.2022.05.014.
   Google Scholar
• Singh A, Ujjwal RR, Naqvi S, et al. Formulation development of tocopherol polyethylene glycol nanoengineered polyamidoamine dendrimer for neuroprotection and treatment of Alzheimer disease. J Drug Target. 2022;1–17. https://doi.org/10.1080/1061186X.2022.2063297.
   Google Scholar
• Mahmoudi A, Kesharwani P, Majeed M, et al. Recent advances in nanogold as a promising nanocarrier for curcumin delivery. Colloids Surfaces B Biointerfaces. 2022;215:112481. https://doi.org/10.1016/J.COLSURFB.2022.112481.
   PubMed Web of Science ®Google Scholar
• Fatima M, Sheikh A, Hasan N, et al. Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors. Eur Polym J. 2022;170:111156. https://doi.org/10.1016/J.EURPOLYMJ.2022.111156.
   Web of Science ®Google Scholar
• Farhoudi L, Kesharwani P, Majeed M, et al. Polymeric nanomicelles of curcumin: potential applications in cancer. Int J Pharm. 2022;617:121622. https://doi.org/10.1016/J.IJPHARM.2022.121622.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Md S, Kesharwani P. Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer. Biomed Pharmacother. 2022;146:112530. https://doi.org/10.1016/J.BIOPHA.2021.112530.
   PubMed Web of Science ®Google Scholar
• Sheikh A, Md S, Kesharwani P. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. J Control Release. 2021;340:221–242. https://doi.org/10.1016/J.JCONREL.2021.10.028.
   PubMed Web of Science ®Google Scholar
• Chadar R, Afzal O, Alqahtani SM, et al. Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy. Colloids Surf B Biointerfaces. 2021;208:112044. https://doi.org/10.1016/J.COLSURFB.2021.112044.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–358. https://doi.org/10.4103/0250-474X.57282.
   PubMed Web of Science ®Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5(3):305–313. https://doi.org/10.15171/APB.2015.043.
   PubMed Web of Science ®Google Scholar
• Singh V, Md S, Alhakamy NA, et al. Taxanes loaded polymersomes as an emerging polymeric nanocarrier for cancer therapy. Eur Polym J. 2022;162:110883. https://doi.org/10.1016/J.EURPOLYMJ.2021.110883.
   Web of Science ®Google Scholar
• Madamsetty VS, Tavakol S, Moghassemi S, et al. Chitosan: a versatile bio-platform for breast cancer theranostics. J Control Release. 2022;341:733–752. https://doi.org/10.1016/J.JCONREL.2021.12.012.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014;39(2):268–307. https://doi.org/10.1016/j.progpolymsci.2013.07.005.
   Web of Science ®Google Scholar
• Amjad MW, Kesharwani P, Mohd Amin MCI, et al. Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy. Prog Polym Sci. 2017;64:154–181. https://doi.org/10.1016/j.progpolymsci.2016.09.008.
   Web of Science ®Google Scholar
• Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33(29):7138–7150. https://doi.org/10.1016/j.biomaterials.2012.06.068.
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Banerjee S, Gupta U, et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater Today. 2015;18(10):565–572. https://doi.org/10.1016/j.mattod.2015.06.003.
   Web of Science ®Google Scholar
• Kesharwani P, Choudhury H, Meher JG, et al. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog Mater Sci. 2019;103:484–508. https://doi.org/10.1016/j.pmatsci.2019.03.003.
   Web of Science ®Google Scholar
• Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288–303. https://doi.org/10.4103/1735-5362.235156.
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9(5):497–508. https://doi.org/10.1517/17425247.2012.673278.
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev. 2020;154-155:64–78. https://doi.org/10.1016/J.ADDR.2020.07.022.
   PubMed Web of Science ®Google Scholar
• Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–191. https://doi.org/10.4103/2230-973X.167661.
   PubMed Web of Science ®Google Scholar
• Yanar F, Mosayyebi A, Nastruzzi C, et al. Continuous-flow production of liposomes with a millireactor under varying fluidic conditions. Pharmaceutics. 2020;12(11):1001–1021. https://doi.org/10.3390/PHARMACEUTICS12111001.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. https://doi.org/10.3389/fphar.2015.00286.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22–36. https://doi.org/10.1016/j.jconrel.2014.04.015.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv. 2014;21(2):87–100. https://doi.org/10.3109/10717544.2013.838077.
   PubMed Web of Science ®Google Scholar
• Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5(4):523–528. https://doi.org/10.2217/NNM.10.23.
   PubMed Web of Science ®Google Scholar
• Dalby B, Cates S, Harris A, et al. Advanced transfection with lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods. 2004;33(2):95–103. https://doi.org/10.1016/J.YMETH.2003.11.023.
   PubMed Web of Science ®Google Scholar
• Breunig M, Lungwitz U, Liebl R, et al. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A. 2007;104(36):14454–14459. https://doi.org/10.1073/PNAS.0703882104.
   PubMed Web of Science ®Google Scholar
• Nunes SS, Miranda SEM, de Oliveira Silva J, et al. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother. 2021;144:112317. https://doi.org/10.1016/J.BIOPHA.2021.112317.
   PubMed Web of Science ®Google Scholar
• Sharma S, Xing F, Liu Y, et al. Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in bone. J Biol Chem. 2016;291(37):19351–19363. https://doi.org/10.1074/JBC.M116.737379.
   PubMed Web of Science ®Google Scholar
• Givens BE, Naguib YW, Geary SM, et al. Nanoparticle based delivery of CRISPR/Cas9 genome editing therapeutics. AAPS J. 2018;20(6):108. https://doi.org/10.1208/S12248-018-0267-9.
   PubMed Web of Science ®Google Scholar
• Ashok B, Peppas NA, Wechsler ME. Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9. J Drug Deliv Sci Technol. 2021;65:102728. https://doi.org/10.1016/J.JDDST.2021.102728.
   PubMed Web of Science ®Google Scholar
• Wang SW, Gao C, Zheng YM, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer. 2022;21(1):57. https://doi.org/10.1186/S12943-022-01518-8.
   PubMed Web of Science ®Google Scholar
• Glass Z, Lee M, Li Y, et al. Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol. 2018;36(2):173–185. https://doi.org/10.1016/J.TIBTECH.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Kazemian P, Yu SY, Thomson SB, et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol Pharmaceutics. 2022;19(6):1669–1686. https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00916/ASSET/IMAGES/MEDIUM/MP1C00916_0003.GIF.
   PubMed Web of Science ®Google Scholar
• Li C, Yang T, Weng Y, et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact Mater. 2022;9:590–601. https://doi.org/10.1016/J.BIOACTMAT.2021.05.051.
   PubMed Web of Science ®Google Scholar
• Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207–218. https://doi.org/10.1016/J.BIOMATERIALS.2018.04.031.
   PubMed Web of Science ®Google Scholar
• Wang M, Zuris JA, Meng F, et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. 2016;113(11):2868–2873. https://doi.org/10.1073/PNAS.1520244113/-/DCSUPPLEMENTAL.
   PubMed Web of Science ®Google Scholar
• Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res. 2019;52(6):1555–1564. https://doi.org/10.1021/ACS.ACCOUNTS.9B00106.
   PubMed Web of Science ®Google Scholar
• Miller JB, Zhang S, Kos P, et al. Non-viral CRISPR/cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed. 2017;56(4):1059–1063. https://doi.org/10.1002/ANIE.201610209.
   PubMed Web of Science ®Google Scholar
• Naeem M, Hoque MZ, Ovais M, et al. Stimulus-Responsive smart nanoparticles-based CRISPR-Cas delivery for therapeutic genome editing. Int J Mol Sci. 2021;22(20):11300. https://doi.org/10.3390/IJMS222011300.
   PubMed Web of Science ®Google Scholar
• Yin H, Song CQ, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328–333. https://doi.org/10.1038/NBT.3471.
   PubMed Web of Science ®Google Scholar
• Cai W, Luo T, Mao L, et al. Spatiotemporal delivery of CRISPR/Cas9 genome editing machinery using stimuli-responsive vehicles. Angew Chem Int Ed Engl. 2021;60(16):8596–8606. https://doi.org/10.1002/ANIE.202005644.
   PubMed Web of Science ®Google Scholar
• Chang J, Chen X, Glass Z, et al. Integrating combinatorial lipid nanoparticle and chemically modified protein for intracellular delivery and genome editing. Acc Chem Res. 2019;52(3):665–675. https://doi.org/10.1021/ACS.ACCOUNTS.8B00493/ASSET/IMAGES/MEDIUM/AR-2018-004939_0012.GIF.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li B, Luo X, et al. Biodegradable amino-ester nanomaterials for Cas9 mRNA delivery in vitro and in vivo. ACS Appl Mater Interfaces. 2017;9(30):25481–25487. https://doi.org/10.1021/ACSAMI.7B08163.
   PubMed Web of Science ®Google Scholar
• Cho EY, Ryu JY, Lee HAR, et al. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J Nanobiotechnol. 2019;17(1):19–12. https://doi.org/10.1186/S12951-019-0452-8/FIGURES/5.
   PubMedGoogle Scholar
• Zhang Y, Li Z, Milon Essola J, et al. Biosafety materials: ushering in a new era of infectious disease diagnosis and treatment with the CRISPR/Cas system. Biosaf Health. 2022;4(2):70–78. https://doi.org/10.1016/J.BSHEAL.2022.03.010.
   PubMedGoogle Scholar
• Liu S, Cheng Q, Wei T, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat Mater. 2021;20(5):701–710. https://doi.org/10.1038/s41563-020-00886-0.
   PubMed Web of Science ®Google Scholar
• Wirsching HG, Weller M. Glioblastoma. In: Moliterno Gunel J, Piepmeier J, Baehring J, editors. Malignant brain tumors state-of-the-art treat. Cham, Switzerland: Springer; 2017. p. 265–288. https://doi.org/10.1007/978-3-319-49864-5_18.
   Google Scholar
• Rosenblum D, Gutkin A, Kedmi R, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020;6(47):9450–9468. https://doi.org/10.1126/SCIADV.ABC9450/SUPPL_FILE/ABC9450_SM.PDF.
   Web of Science ®Google Scholar
• Wang CS, Chang CH, Tzeng TY, et al. Gene-editing by CRISPR–Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and nucleus-directed nanoparticles for head and neck cancer suppression. Nanoscale Horiz. 2021;6(9):729–743. https://doi.org/10.1039/D1NH00254F.
   PubMed Web of Science ®Google Scholar
• Fan J, Liu Y, Liu L, et al. A multifunction lipid-based CRISPR-Cas13a genetic circuit delivery system for bladder cancer gene therapy. ACS Synth Biol. 2020;9(2):343–355. https://doi.org/10.1021/ACSSYNBIO.9B00349/SUPPL_FILE/SB9B00349_SI_001.PDF.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet (London, England). 2014;384(9951):1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7.
   PubMed Web of Science ®Google Scholar
• Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. https://doi.org/10.1146/ANNUREV.PATHOL.4.110807.092246.
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078–1094. https://doi.org/10.1038/s41578-021-00358-0.
   PubMed Web of Science ®Google Scholar
• Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–644. https://doi.org/10.1016/J.CCM.2011.09.001.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA. CA Cancer J Clin. 2011;61(4):212–236. https://doi.org/10.3322/CAAC.20121.
   PubMed Web of Science ®Google Scholar
• Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Prim. 2015; 1(2015):1–18. https://doi.org/10.1038/nrdp.2015.17.
   Google Scholar
• Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297. https://doi.org/10.1007/S13311-017-0519-X/TABLES/2.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109(1):93–108. https://doi.org/10.1007/S00401-005-0991-Y.
   PubMed Web of Science ®Google Scholar
• Chai RC, Lambie D, Verma M, et al. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med. 2015;4(4):596–607. https://doi.org/10.1002/CAM4.424.
   PubMed Web of Science ®Google Scholar
• Kwan ML, Garren B, Nielsen ME, et al. Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer. Urol Oncol. 2019;37(6):380–386. https://doi.org/10.1016/J.UROLONC.2018.03.019.
   PubMed Web of Science ®Google Scholar